Extended Data Table 3 Individual anti-drug antibody (ADA) ratio of cynomolgus monkeys treated with CD123-NKCE

From: Control of acute myeloid leukemia by a trifunctional NKp46-CD16a-NK cell engager targeting CD123

  1. Individual anti-drug antibody (ADA) ratio (fold-change from baseline value collected at Day 1 Predose) after a weekly repeat 1-hour intravenous infusion of CD123-NKCE at 0.1 and 3 mg/kg/administration for 4 weeks (on Days 1, 8, 15 and 22) to cynomolgus monkeys are shown. Under the assay conditions, the presence of ADA is considered to be significant when the ADA ratio is above 3.0 or, for ratio below 3.0, when the ratio increase with time.
Back to article page